Skip to content
Bored Studies
RecruitingPhase 2

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

Biocomposites Ltd · with MCRA · NCT06283979

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
60
US sites recruiting
9
Study start
June 15, 2025
Record last updated
May 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.

Being studied: STIMULAN VG; Standard of Care

Conditions: Pressure Ulcer, Stage IV; Osteomyelitis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

  • Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
  • Operative candidate for flap surgery or primary closure.
  • Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
  • Adults ≥ 18 years in age at the time of treatment.
  • Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
  • Ability of the subject or legal authorized representative to provide voluntary, signed and dated informed consent prior to any study-related procedures.

Subjects who meet any of the following criteria will be excluded from participating in this study:

  • Reasons contributing to pressure ulcer cannot be addressed.
  • Severe immunological compromised patients as determined by the clinician.
  • Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
  • Patients presenting with head pressure ulcers.
  • Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
  • Current smoker.
  • Diabetic patient with Hba1C level above 9.
  • Allergy to any component of the investigational product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
  • Concurrent involvement in a study of another investigational product.
  • Pregnant or planning to become pregnant during study period.
  • Flexion contractures where patient cannot passively get full extension.
  • Uncontrolled muscle spasms.
  • Unable to comply with bedrest restriction or offloading requirements
  • Unable to provide consent.
  • Fecal or urinary incontinence with contamination of the wound.
  • Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg *
  • Investigator considers the participant to be clinically malnourished.
  • Any conditions with known hypercalcemia (> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
  • Investigator believes trial participation may compromise safety of the participant or trial results.
  • Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization

Recruiting US locations

  • Advanced Foot Care, LLC

    Phoenix, AZ 85032

    Site contact: Krishna Sai Penumarthi · (480) 863-6044 · kspenumarthi@axentrabio.com

  • Northwestern University Feinberg School of Medicine

    Chicago, IL 60611

    Site contact: Brigid Coles · 312-503-3209 · brigid.coles@nm.org

  • Henry Ford Hospital

    Detroit, MI 48202

    Site contact: Dan Molitor · dmolito2@hfhs.org

  • University of Mississippi Medical Center

    Jackson, MS 39216

    Site contact: Venkata Seerapu · vseerapu@umc.edu

  • Missouri Orthopaedic Institute

    Columbia, MO 65201

    Site contact: Andrew Monhollen · am5hf@health.missouri.edu

  • University of Nebraska Medical Center

    Omaha, NE 68198

    Site contact: Katie Ostlund · katie.ostlund@unmc.edu

  • Rutgers New Jersey Medical School

    Newark, NJ 07103

    Site contact: Saharsh Patel · ssp186@gsbs.rutgers.edu

  • NYU Langone Hospital - Long Island Clinical Research Center

    Mineola, NY 11501

    Site contact: Anita Farha · 516 663 9582 · anita.farhi@nyulangone.org

  • University of Pittsburgh, McGowan Institute for Regenerative Medicine

    Pittsburgh, PA 15219

    Site contact: Urmila Gnyawali · 412-624-5500 · usg2@pitt.edu

Study contacts (from the official record)

  • Keira Watts, Clinical Research Director · +44 (0) 1782 338 580 · clinicaltrials@biocomposites.com
  • Daniel Roberts · droberts@mcra.com
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard… (NCT06283979) | Bored Studies